Determining the VEGF-C/VEGFR-3 expression status may help predict which patients will develop regional recurrence and provide novel targets for therapies to suppress lymph node metastasis in the treatment of OTSCC. Here, FLT4 is linked to metastatic malignant neoplasm in the lymph nodes.